A novel “reduced immunogenicity” bispecific targeted toxin simultaneously recognizing human EGF and IL-4 receptors in a mouse model of metastatic breast carcinoma

Eitemau Tebyg

• Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity
  gan: Stish, B J, et al.
  Cyhoeddwyd: (2009)
• Bioengineering a unique deimmunized bispecific targeted toxin that simultaneously recognizes human CD22 and CD19 receptors in a mouse model of B cell metastases
  gan: Vallera, Daniel A., et al.
  Cyhoeddwyd: (2010)
• A new drug delivery method of bispecific ligand-directed toxins that reduces toxicity and promotes efficacy in a model of orthotopic pancreatic cancer
  gan: Oh, Seunguk, et al.
  Cyhoeddwyd: (2010)
• A novel bispecific ligand-directed toxin designed to simultaneously target EGFR on human glioblastoma cells and uPAR on tumor neovasculature
  gan: Tsai, Alexander K., et al.
  Cyhoeddwyd: (2010)
• Genetically designing a more potent anti-pancreatic cancer agent by simultaneously cotargeting human IL-13 and EGF receptors in a mouse xenograft model
  gan: Vallera, Daniel A, et al.
  Cyhoeddwyd: (2008)